SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-17-067391
Filing Date
2017-11-09
Accepted
2017-11-09 16:20:08
Documents
51
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a17-20673_110q.htm 10-Q 1039227
2 EX-10.2 a17-20673_1ex10d2.htm EX-10.2 133083
3 EX-31.1 a17-20673_1ex31d1.htm EX-31.1 13097
4 EX-31.2 a17-20673_1ex31d2.htm EX-31.2 13074
5 EX-32.1 a17-20673_1ex32d1.htm EX-32.1 6451
6 EX-32.2 a17-20673_1ex32d2.htm EX-32.2 6911
  Complete submission text file 0001104659-17-067391.txt   4090524

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT nbrv-20170930.xml EX-101.INS 723772
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nbrv-20170930.xsd EX-101.SCH 32369
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nbrv-20170930_cal.xml EX-101.CAL 45119
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nbrv-20170930_def.xml EX-101.DEF 113955
11 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nbrv-20170930_lab.xml EX-101.LAB 309043
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nbrv-20170930_pre.xml EX-101.PRE 240176
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 171191123
SIC: 2834 Pharmaceutical Preparations